119 related articles for article (PubMed ID: 38565644)
1. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
Agusti N; Kanbergs A; Nitecki R
Gynecol Oncol; 2024 Jun; 185():121-127. PubMed ID: 38402734
[TBL] [Abstract][Full Text] [Related]
2. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
3. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gunderson CC; Fader AN; Carson KA; Bristow RE
Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z; Wu Z; Liu W; Ning Y; Liu J; Ding W; Fan J; Cai S; Li Q; Li W; Yang X; Dou Y; Wang W; Peng W; Lu F; Zhuang X; Qin T; Kang X; Feng C; Xu Z; Lv Q; Wang Q; Wang C; Wang X; Wang Z; Wang J; Jiang J; Wang B; Mills GB; Ma D; Gao Q; Li K; Chen G; Chen X; Sun C
Nat Genet; 2024 Apr; 56(4):637-651. PubMed ID: 38565644
[TBL] [Abstract][Full Text] [Related]
5. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
6. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
7. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
8. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
9. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
10. Endometrium-derived mesenchymal stem cells suppress progression of endometrial cancer via the DKK1-Wnt/β-catenin signaling pathway.
Xu Y; Hu J; Lv Q; Shi C; Qiu M; Xie L; Liu W; Yang B; Shan W; Cheng Y; Zhao B; Chen X
Stem Cell Res Ther; 2023 Jun; 14(1):159. PubMed ID: 37287079
[TBL] [Abstract][Full Text] [Related]
11. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF
Elez E; Ros J; Fernández J; Villacampa G; Moreno-Cárdenas AB; Arenillas C; Bernatowicz K; Comas R; Li S; Kodack DP; Fasani R; Garcia A; Gonzalo-Ruiz J; Piris-Gimenez A; Nuciforo P; Kerr G; Intini R; Montagna A; Germani MM; Randon G; Vivancos A; Smits R; Graus D; Perez-Lopez R; Cremolini C; Lonardi S; Pietrantonio F; Dienstmann R; Tabernero J; Toledo RA
Nat Med; 2022 Oct; 28(10):2162-2170. PubMed ID: 36097219
[TBL] [Abstract][Full Text] [Related]
12. Is early-onset cancer an emerging global epidemic? Current evidence and future implications.
Ugai T; Sasamoto N; Lee HY; Ando M; Song M; Tamimi RM; Kawachi I; Campbell PT; Giovannucci EL; Weiderpass E; Rebbeck TR; Ogino S
Nat Rev Clin Oncol; 2022 Oct; 19(10):656-673. PubMed ID: 36068272
[TBL] [Abstract][Full Text] [Related]
13. AACR Project GENIE: 100,000 Cases and Beyond.
Pugh TJ; Bell JL; Bruce JP; Doherty GJ; Galvin M; Green MF; Hunter-Zinck H; Kumari P; Lenoue-Newton ML; Li MM; Lindsay J; Mazor T; Ovalle A; Sammut SJ; Schultz N; Yu TV; Sweeney SM; Bernard B;
Cancer Discov; 2022 Sep; 12(9):2044-2057. PubMed ID: 35819403
[TBL] [Abstract][Full Text] [Related]
14. Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.
Safdar NS; Stasenko M; Selenica P; Martin AS; da Silva EM; Sebastiao APM; Krystel-Whittemore M; Abu-Rustum NR; Reis-Filho JS; Soslow RA; Shen R; Mueller JJ; Oliva E; Weigelt B
J Natl Cancer Inst; 2022 Nov; 114(11):1545-1548. PubMed ID: 35699480
[TBL] [Abstract][Full Text] [Related]
15. Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos D; Zappasodi R; Schulze I; Sethna Z; de Andrade KC; Bajorin DF; Bandlamudi C; Callahan MK; Funt SA; Hadrup SR; Holm JS; Rosenberg JE; Shah SP; Vázquez-García I; Weigelt B; Wu M; Zamarin D; Campitelli LF; Osborne EJ; Klinger M; Robins HS; Khincha PP; Savage SA; Balachandran VP; Wolchok JD; Hellmann MD; Merghoub T; Levine AJ; Łuksza M; Greenbaum BD
Nature; 2022 Jun; 606(7912):172-179. PubMed ID: 35545680
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
